secwatch.observer — SEC 8-K summary
======================================

Issuer:     RAPID MICRO BIOSYSTEMS, INC. (RPID)
CIK:        0001380106
Form:       8-K
Filed at:   2022-05-10T23:59:59+00:00
Accession:  0001380106-22-000026
Event type: earnings
Sentiment:  negative
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Rapid Micro Biosystems Q1 commercial revenue $4.2M, down from $4.8M; reaffirms FY2022 revenue $27-32M
--------------------------------------------------------------------------------

- Commercial revenue $4.2M (Q1 2021: $4.8M, including $0.2M BARDA); recurring revenue up 66% to $2.7M.
- Net loss ($14.9M) vs ($22.1M) prior year; EPS ($0.35) reflecting higher share count after IPO.
- Cash and investments $184.2M, no debt; reaffirms FY2022 revenue guidance $27-32M (growth 25-50%).
- Placed 2 systems, completed validation of 9 systems; expects Q2 system placements similar to Q1.
- Beta testing of rapid sterility system with global top 20 pharma expected to begin later in Q2.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1380106/000138010622000026/0001380106-22-000026-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1380106/000138010622000026/c106-20220510x8k.htm
  HTML page:      https://secwatch.observer/filing/0001380106-22-000026

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer